Cencora, Inc. (NYSE:COR) Shares Sold by Fmr LLC

Fmr LLC reduced its holdings in shares of Cencora, Inc. (NYSE:COR) by 21.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 4,103,921 shares of the company’s stock after selling 1,089,917 shares during the period. Fmr LLC’s holdings in Cencora were worth $923,710,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. New Millennium Group LLC bought a new position in Cencora during the 2nd quarter valued at $26,000. MFA Wealth Advisors LLC acquired a new stake in shares of Cencora in the 2nd quarter valued at about $30,000. Concord Wealth Partners bought a new position in shares of Cencora during the third quarter worth about $30,000. LRI Investments LLC acquired a new position in Cencora in the first quarter worth about $31,000. Finally, SYSTM Wealth Solutions LLC bought a new stake in Cencora in the second quarter valued at about $36,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the sale, the chairman now owns 306,752 shares of the company’s stock, valued at $74,283,064.32. The trade was a 6.55 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 93,018 shares of company stock worth $22,478,942. Company insiders own 15.80% of the company’s stock.

Analysts Set New Price Targets

COR has been the topic of a number of research analyst reports. UBS Group increased their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Wells Fargo & Company raised their price objective on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. Evercore ISI lifted their price objective on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $271.20.

Cencora Trading Up 0.5 %

Shares of NYSE:COR opened at $249.70 on Thursday. Cencora, Inc. has a fifty-two week low of $195.83 and a fifty-two week high of $251.56. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The company has a market cap of $49.20 billion, a PE ratio of 33.25, a P/E/G ratio of 1.63 and a beta of 0.44. The company’s 50-day moving average price is $233.56 and its 200 day moving average price is $232.01.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.88%. Cencora’s payout ratio is currently 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.